SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-18-178586
Filing Date
2018-05-30
Accepted
2018-05-30 16:36:02
Documents
3
Period of Report
2018-05-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d583298d8k.htm 8-K 22199
2 EX-99.1 d583298dex991.htm EX-99.1 7883
3 GRAPHIC g583298g86n74.jpg GRAPHIC 2098
  Complete submission text file 0001193125-18-178586.txt   34415
Mailing Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 18868605
SIC: 2836 Biological Products, (No Diagnostic Substances)